Clinical effects of sodium-glucose cotransporter 2 inhibitors combined with conventional therapy in myocardial infarction: a systematic review and meta-analysis of randomized controlled trials
Adding a common heart medication class cuts hospitalizations and major cardiac events by a quarter in heart attack survivors, regardless of diabetes status.
A meta-analysis of 13 randomized controlled trials (n=22,238) demonstrates that adding SGLT2 inhibitors to standard post-myocardial infarction therapy significantly reduces heart failure hospitalizations by 24% and MACE by 16%, with benefits observed irrespective of diabetes status or the specific SGLT2i used. These findings substantially expand the evidence base for SGLT2i use in post-MI patients and support near-term guideline updates.
What the study was
- Study design
- Meta-analysis of 13 RCTs
- Population
- Patients with myocardial infarction
- Sample size
- 22238
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Frontiers in Cardiovascular Medicine
Why it surfaced
Meta-analysis of 13 RCTs with n=22,238 demonstrating significant cardiovascular benefit of SGLT2i post-MI; benefit independent of diabetes status makes this directly actionable. Core SGLT2 watchlist topic.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.